(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Higgins DA et al. | MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. | 1996 | Vaccine | pmid:8782343 |
Singh M et al. | A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. | 1998 | Vaccine | pmid:9795387 |
Hilgers LA et al. | Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant. | 1999 | Vaccine | pmid:9987157 |
Podda A | The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. | 2001 | Vaccine | pmid:11257408 |
Greer CE et al. | The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. | 2000 | Vaccine | pmid:11137233 |
Skeiky YA et al. | Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. | 2002 | Vaccine | pmid:12213399 |
Esposito S et al. | Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. | 2010 | Vaccine | pmid:20888873 |
Camilloni B et al. | Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. | 2009 | Vaccine | pmid:19410623 |
Phillips CJ et al. | Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. | 2009 | Vaccine | pmid:19379786 |
Carmona A et al. | Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. | 2010 | Vaccine | pmid:20600478 |
Frey SE et al. | Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. | 2010 | Vaccine | pmid:20619382 |
Dell'Era L et al. | Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. | 2012 | Vaccine | pmid:22138210 |
Guillon C et al. | Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. | 2007 | Vaccine | pmid:17904700 |
Bråve A et al. | Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. | 2007 | Vaccine | pmid:17707956 |
O'Hagan DT et al. | Cationic microparticles are a potent delivery system for a HCV DNA vaccine. | 2004 | Vaccine | pmid:15542189 |
Faenzi E et al. | One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. | 2012 | Vaccine | pmid:22521851 |
Dey AK et al. | Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. | 2012 | Vaccine | pmid:22366638 |
Yang WH et al. | Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. | 2013 | Vaccine | pmid:23856331 |
Calabro S et al. | The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. | 2013 | Vaccine | pmid:23684834 |
Rouleau I et al. | Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. | 2013 | Vaccine | pmid:24144473 |